Recently, receptor tyrosine kinase inhibitors (TKIs) pazopanib and sunitinib have been used to treat metastatic ccRCC via suppressing the function of vascular endothelial growth factor and mechanistic target of rapamycin (mTOR), respectively. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.